Clinical Trial Update: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Pfizer is conducting a Phase 3 study of encorafenib (Braftovi) plus cetuximab, with or without chemotherapy, in previously untreated metastatic colorectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• ERBITUX (cetuximab)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING